巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Vascular Biogenics Ltd

    VBLT
    0.255
    0.010
    5.85%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Vascular Biogenics Ltd - 延遲價格・最後更新於 10/08 12:00
    最高位
    0.259
    最低位
    0.241
    開市價
    --
    前收市價
    0.241
    成交量(千)
    160.35
    成交額(百萬)
    0.39
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    17.69
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    2.540 - 0.210
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Vascular Biogenics Ltd
    證券代碼
    VBLT.US
    所屬板塊
    Biotechnology
    公司業務
    Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.
    發行量
    69326950
    公司總部
    8 HaSatat Street
    公司網址
    https://www.vblrx.com
    公司電郵
    IR@VBLRX.COM
    公司電話
    +972 89935000

    美股異動 | Vascular Biogenics(VBLT.US)盤前跌近80% 卵巢癌藥物未能達到主要終點

    格隆匯·
    美股異動 | Vascular Biogenics(VBLT.US)盤前跌近80% 卵巢癌藥物未能達到主要終點

    美股異動 | Vascular Biogenics(VBLT.US)盤前跌近80% 卵巢癌藥物未能達到主要終點

    格隆匯·
    美股異動 | Vascular Biogenics(VBLT.US)盤前跌近80% 卵巢癌藥物未能達到主要終點

    關於

    Vascular Biogenics Ltd(VBLT.US)所屬的行業板塊為Biotechnology。
    Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.
    詳細公司背景可參考: https://www.vblrx.com